Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
buntanetap + dulaglutide + sildenafil
- Development stage
- Unknown
- Lead developer
- Annovis Bio
- Modality
- Small Molecules, Peptides
- Administration
- Oral, Subcutaneous
01
Overview
Buntanetap + dulaglutide + sildenafil is a triple-combination therapy under development by Annovis Bio for the treatment of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. This multifaceted approach combines buntanetap, which inhibits the translation of neurotoxic proteins such as amyloid-beta, tau, and alpha-synuclein; dulaglutide (Trulicity), a GLP-1 receptor agonist that restores brain glucose metabolism; and sildenafil (Viagra), a PDE5 inhibitor that improves cerebral blood flow. By addressing protein toxicity, metabolic dysfunction, and vascular health simultaneously, the combination aims to restore and potentially enhance cognitive function beyond healthy baseline levels.
- Other names
- buntanetap + Trulicity + Viagrabuntanetap + dulaglutide + sildenafil combination
02
Targets
GLP1R (GLP-1R)IRE (Iron-responsive element)PDE5 (Phosphodiesterase 5A)SNCA (Alpha-synuclein)Aβ (Amyloid-beta peptides and aggregates)TARDBP (TAR DNA-binding protein 43)MAPT (Microtubule-associated protein tau)
Beyond the preview
Go deeper on buntanetap + dulaglutide + sildenafil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on buntanetap + dulaglutide + sildenafil.